Core Viewpoint - Rapport Therapeutics, Inc. has initiated an underwritten public offering of $250 million in common stock, with an additional option for underwriters to purchase up to $37.5 million more [1][2]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [5]. - The company utilizes a RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain, aiming to create precision small molecule candidates that address limitations in conventional neurology drug discovery [5]. - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for conditions such as drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [5]. Offering Details - The public offering is subject to market conditions, and there is no guarantee regarding its completion or the final terms [1]. - The offering is conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3].
Rapport Announces Proposed Public Offering of Common Stock